Innovative Therapy Salvia BioElectronics has developed a breakthrough drug-free neuromodulation implant for chronic migraine, presenting a compelling upgrade opportunity for healthcare providers seeking advanced non-pharmacological treatment options.

Rapid Growth With a successful Series B funding of $60 million and recent award recognition, the company is scaling its clinical development and manufacturing capabilities, indicating expanding sales and adoption potential in international markets including the US, Europe, and Australia.

Expanding Market The company’s exploration into treatments for other neural conditions like cluster headaches broadens its market scope, creating potential upsell or cross-sell opportunities with neurologists and headache specialists.

Tech Ecosystem Salvia's use of advanced technology platforms such as AWS and GDPR compliance underscores its readiness to integrate with healthcare IT systems, offering opportunities to collaborate with digital health platforms and medical device integrators.

Strategic Positioning As a clinical-stage company with a focus on innovative neuromodulation, Salvia presents an attractive partnership prospect for medical device distributors and strategic investors looking to expand their portfolio in the neurology and MedTech sectors.